This study aimed to determine the impact of blood stream infections (BSIs) on outcome of allogeneic hematopoietic SCT (HSCT), and to examine the influence of old (nonlevofloxacin-containing) and new (levofloxacin-based) prophylactic antibiotic protocols on the pattern of BSIs. We retrospectively enrolled 246 allogeneic HSCT recipients between January 1999 and June 2006, dividing patients into BSI (within 6 months post-HSCT, n ¼ 61) and non-BSI groups (n ¼ 185). We found that Gramnegative bacteria (GNB) predominated BSI pathogens (54%). Multivariate analyses showed that patients with a BSI, compared with those without, had a significantly greater 6-month mortality (hazard ratio, 1.75; 95% confidence interval, 1.09-2.82; P ¼ 0.021) and a significantly increased length of hospital (LOH) stay (70.8 vs 55.2 days, P ¼ 0.014). Moreover, recipients of old and new protocols did not have a significantly different 6-month mortality and time-to-occurrence of BSIs. However, there were significantly more resistant GNB to third-generation cephalosporins and carbapenem in recipients of levofloxacin-based prophylaxis. Our data suggest that BSIs occur substantially and impact negatively on the outcome and LOH stay after allogeneic HSCT despite antibiotic prophylaxis. Levofloxacin-based prophylaxis, albeit providing similar efficacy to non-levofloxacin-containing regimens, may be associated with increased antimicrobial resistance.
Introduction
Despite major progress in managing the complications of hematopoietic SCT (HSCT), blood stream infection (BSI) remains one of the most common serious infectious complications of HSCT, occurring at an incidence ranging between 13À60% among all HSCT recipients. [1] [2] [3] [4] [5] There are well-known risk factors for BSIs in allogeneic HSCT recipients, including prolonged neutropenia, intensive chemotherapy-related mucositis, indwelling central venous lines, development of acute GVHD and other periengraftment complications. [4] [5] [6] [7] The use of prophylactic antibiotics in HSCT recipients has been an important measure reducing the risk of BSIs, particularly in the allogeneic setting. [7] [8] [9] [10] [11] [12] Since the early 1970s, selective gut decontamination, aiming to suppress overgrowth and translocation of intestine aerobic microflora, has been suggested for reducing BSIs in HSCT recipients, particularly threats from Gram-negative pathogens. [13] [14] [15] [16] [17] [18] Combination regimens with oral non-absorbable or partly absorbable antimicrobials, such as trimethoprim sulfamethoxazole (TMP-SMX), metronidazole, vancomycin, nystatin, nalixidic acid or pipemidic acid and so on, were commonly used in the early decades. 13, 19, 20 After the 1980s, newer generations of fluoroquinolones, such as ciprofloxacin and levofloxacin, have been one of the most commonly used drugs because of their better compliance compared with non-absorbable regimens. 11, 13, 19 Despite the advantage of antibiotic prophylaxis, 13 a major concern remains on the potential of antibiotic prophylaxis to increase antibacterial resistance, particularly the influence of fluoroquinolone exposure. [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] For example, emergence of fluoroquinoloneresistant bacteria in neutropenic patients receiving fluoroquinolone prophylaxis has been well-documented. [21] [22] [23] [24] [25] [26] [27] [28] [29] Furthermore, the occurrence of cross-resistant or multiple-drug-resistant (MDR) pathogens, such as an increase in MDR Gram-negative bacteria (GNB), 30, [35] [36] [37] [38] increase in nosocomial methicillin-resistant Staphylococcus aureus infections 31, 33, 34, 38, 39 and an emergence of extended spectrum beta-lactamase producers, 32 have all been reported in literature.
The study aimed to determine the impact of BSIs on outcomes of allogeneic HSCT recipients who had received antibiotic prophylaxis, with a specific focus on mortality and length of hospital (LOH) stay. A second objective was to examine whether the use of old (non-levofloxacincontaining) and new (levofloxacin-based) antibiotic prophylactic regimens in our institute during the aplastic phase of allogeneic HSCT would result in a difference with respect to time-to-occurrence of BSIs and/or mortality after HSCT, as well as the antibiotic susceptibility patterns of isolated BSI pathogens.
Patients and methods
This study, approved by the Institutional Review Board of Taipei Veterans General Hospital, was a retrospective cohort analysis conducted between January 1999 and June 2006. Included were consecutive patients who underwent allogeneic HSCT in the BMT Unit at Taipei Veterans General Hospital, a specialized unit equipped with positive air pressure and high-efficiency particulate air filtration. The demographic data and clinical characteristics of the study population were obtained from clinical chart review, HSCT registry information and physician records. Patient records were reviewed for at least 6 months unless death occurred before completion.
Definitions
A BSI was defined as previously described. 40 Acute GVHD was defined and graded according to the consensus criteria. 41 For purposes of statistical analysis, the maximum grade of acute GVHD was used. The diagnoses of hepatic veno-occlusive disease, 42 CMV infection 43, 44 and invasive aspergillosis 45 were based on published criteria or definitions. Catheter-related infections were defined as previously described. 39, 46 Hickman catheters were used for allogeneic HSCT in the current study and non-infected Hickman catheters were generally removed within 3 months post-HSCT. The hematological disease status at the time of HSCT was defined as either early or late status according to Parody et al. 47 In antibiotic susceptibility tests, pathogens with intermediate susceptibility or resistance were considered to be resistant. The definitions of Gram-negative, extended spectrum beta-lactamase producers and MDR GNB were defined according to Mikulska et al. 
Transplantation procedures
Transplantation was performed according to our institutional protocols and on the basis of underlying hematological diseases. All patients signed an informed consent before HSCT. Briefly, the most frequent myeloablative conditioning regimens included BuCy and CyTBI. The BuCy regimen consisted of BU (1 mg/kg per os or 0.8 mg/ kg i.v. 4 times a day for 4 days) and CY (60 mg/kg per day i.v. for 2 days). The CyTBI regimen consisted of TBI (900À1200 cGy in 3À4 days) and CY (60 mg/kg i.v. per day for 2 days). The reduced intensity regimen consisted mostly of i.v. fludarabine (180 mg/m 2 in 6 days) with BU (8 mg/kg per os in 2 days) and antithymocyte globulin (ATGFresenius, 10 mg/kg per day for 4 days; Fresenius-Biotech, Graefelfing, Germany). Standard GVHD prophylaxis included CYA and MTX. Antithymocyte globulin (ATGFresenius; Fresenius-Biotech) at 45 mg/kg in 3 days was administered to HSCT recipients with an unrelated HLAidentical donor. Management of acute GVHD was based on corticosteroids according to the severity of acute GVHD.
Antibiotic prophylaxis and management of infections
Since the 1990s, oral antibiotic prophylaxis has been a routine pre-transplant measure for patients undergoing allogeneic HSCT in our institute. A combination of prophylactic antibiotic was applied to all patients upon entry into conditioning before HSCT (from day À8 to day À7 depending on conditioning regimens) and was continued until the day of neutrophil recovery (an ANC of 41500 /mL) or occurrence of febrile neutropenia. An old protocol (non-fluoroquinolone-based) was followed until September 2002, which consisted of an oral combination of nystatin gargle, oral TMP-SMX and vancomycin. A new protocol (fluoroquinolone-based) has been followed since 1 September 2002, consisting of a combination of oral fluconazole, oral levofloxacin, oral TMP-SMX and oral metronidazole. After engraftment, patients received prophylaxis against Pneumocystis jiroveci with TMP-SMX for 6 months to 1 year. CMV prophylaxis was not routinely used, given the very high seroprevalence of CMV in adults in Taiwan 48, 49 and the relatively low incidence of post-HSCT CMV infections in our institute. 43, 50 However, preemptive anti-CMV therapy with gancyclovir was initiated at first detection of CMV reactivation by a rapid diagnostic technique with quantitative real-time PCR assays for CMV DNA. In the case of fever or other signs and/or symptoms of infection, prophylactic antibiotics were discontinued and patients were treated with broad-spectrum i.v. antibiotics. The use of empirical antibiotics was on an individual basis and in accordance with the guidelines. [51] [52] [53] Briefly, the choice of antibiotic monotherapy in non-cephalosporine allergic patients included cefepime, cefpirome, piperacillin/ tazobactam or carbapenem, whereas the choice of combination therapy included a combination of an aminoglycoside with ceftazidime, cefepime, cefpirome, piperacillin/ tazobactam or carbapenem. A glycopeptide such as teicoplanin or vancomycin was added when deemed necessary. Antibiotics were modified according to the susceptibility of all organisms isolated. All infected catheters were removed.
Statistical and survival analysis
Patients were separated into BSI (within 6 months post-HSCT) and non-BSI groups. Patients who were lost to follow-up before 6 months post-HSCT were excluded from survival analysis. Data and survival analyses were compared between the two groups. End points included 6-month mortality and LOH within 6 months post-HSCT. The correlations of variables between the BSI and non-BSI groups were analyzed by a w 2 test or Fisher's exact test (two-sided), as appropriate. OS was measured from the date of HSCT to the date of death, and patients alive at 6 months post-HSCT were censored. Survival was estimated using the Kaplan-Meier method and the log-rank test was used for comparison of survival curves. The Cox proportional hazards model was applied for univariate and multivariate analyses to determine the prognostic influence of variables on survival end points. Variables with P values o0.10 on univariate analyses were entered into multivariate analyses. Linear regression model was used to identify the factors associated with increased LOH stay. Multiple linear regression analysis was used for testing the effect of each significant factor adjusted for the other factors. For analyzing the influence of the old and new prophylactic antibiotic protocols, a w 2 test or Fisher's exact test (two-sided) was used for comparing the microbiology and antibiotic susceptibility of BSI isolates between the two groups. Logistic regression analysis was used to estimate the odds ratio of the new prophylactic protocol toward the former protocol with respect to risk of BSI occurrence. In addition, the time to BSI occurrence was compared using a log rank test. A P value o0.05 was regarded as statistically significant in two-tailed tests. SPSS software (version 13.00; SPSS Inc., Chicago, IL, USA) was used for all statistical analyses.
Results

General characteristics
During the study period, 246 allogeneic HSCT recipients (61 in the BSI group and 185 in the non-BSI group) were enrolled. The median age at HSCT was 30 years (interquartile range, 19-44 years). Table 1 displays the characteristics of the study population. The characteristics of patients, HSCT and non-BSI infections were generally comparable between the BSI and non-BSI groups, except that there were significantly more males and catheterrelated infections in the BSI groups (Table 1) .
Outcome analyses
BSIs were significantly associated with increased 6-month mortality after HSCT. A total of 76 (30.9%) patients died within 6 months, among whom 43 (56.6%) patients succumbed in the first 3 months and 33 patients (43.4%) died in the next 3 months (Figure 1a) . The 61 patients with BSIs had 77 episodes of BSIs; 49 patients (80.3%) had a single episode, 8 (13.1%) patients had 2 episodes and 4 patients (6.6%) had 3 episodes of BSIs. In all, 28 patients (45.9%) developed BSIs within 30 days of HSCT (Figure 1b) . There was one patient in the BSI group and two patients in the non-BSI group who were lost to followup before 6 months post-HSCT, and thus were not included in the survival analysis. Figure 2a shows that patients with BSIs had a significantly worse 6-month survival than those without BSIs. Furthermore, the post-HSCT 6-month survival curves did not differ significantly among patients with a GNB BSI alone, Gram-positive bacteria BSI alone or others (Figure 2b ). Table 2 summarizes the results of univariate and multivariate analyses of potential factors associated with the 6-month mortality. In the multivariate model, after controlling for underlying lymphoma, venoocclusive disease, disease status at the time of HSCT and invasive aspergillosis, a BSI was independently associated with 6-month mortality (hazard ratio 1.75, 95% confidence interval, 1.09À2.82, P ¼ 0.021; Table 2 ).
BSI significantly associated with increased LOH stays after HSCT Simple linear regression analyses showed that in addition to BSI, age at HSCT o18 years, graft type of BM, presence of acute GVHD, catheter-related infection and CMV infection were significantly associated with an increased LOH stay after HSCT (Table 3) . Multiple linear regression analysis revealed that BSI in 6 months (P ¼ 0.014), after adjusted for CMV infection in 6 months (Po0.001), presence of acute GVHD (Po0.001) and catheter-related infection (P ¼ 0.018), remained significant in association with increased LOH stays after HSCT.
The influence of prophylactic antibiotic protocols on BSI events, the time to BSI, microbiology and antibiotic susceptibility Logistic regression analysis revealed that recipients of the new prophylactic protocol did not differ significantly from those who received the old prophylactic protocol (odds ratio 1.20; 95% confidence interval, 0.67À2.14; P ¼ 0.535) with respect to the risk of BSI occurrence. Moreover, there was no difference in the time to the first BSI event according to recipients of the old and new protocols. Among the 88 isolates retrieved from the blood of 61 BSI patients, 47 isolates (53.4%) were GNB, 32 (36.4%) were Gram-positive bacteria and 9 (10.2%) were fungi. There were no significant differences between the new and old protocols of antibiotic prophylaxis with respect to Gram-negative or Gram-positive pathogens (Table 4) . Moreover, the quinolone-resistant or TMP-SMX-resistant strains among the Gram-negative or Gram-positive pathogens were not different based on the protocols introduced (Table 4 ). In general, the development of bacteremia after or during the course of prophylactic antibiotics was highly resistant to TMP-SMX (63.8% resistant Gram-negative and 62.5% resistant Gram-positive strains, respectively). A total of 33 (70%) Gram-negative isolates and all (100%) Gram-positive isolates remained sensitive to levofloxacin, suggesting that the breakthrough of prophylactic antibiotic protection could not be fully explained by the development of antibiotic resistance to the drugs used. When further examining the antibiotic susceptibility of Gram-negative pathogens, we found that in the cultured Gram-negative pathogens within the new (levofloxacin-based) protocol group, there were significantly more GNB resistant to third-generation cephalosporins (in general) and to carbapenem (P ¼ 0.01 and 0.026, respectively), whereas there was a borderline increase in MDR and ceftazidime-resistant strains (P ¼ 0.056 and P ¼ 0.056, respectively), as shown in Table 5 . The characteristics between recipients of the old and new protocols of antibiotic prophylaxis Since the study covered the period from 1999 to 2006, and there might have been changes in the patient population and underlying risk factors that might impact any potential benefit of the new regimen, we examined the characteristics between recipients of the old and new protocol periods. The baseline characteristics, post-HSCT complications and BSI characteristics were generally similar, except that patients with lymphoma were more (n ¼ 8 (7%) vs n ¼ 24 (18%), P ¼ 0.018) and CMV infection occurred more (n ¼ 17 (15%) vs n ¼ 36 (27%), P ¼ 0.033) in the new protocol period. The difference of CMV infection between the two periods seems unrelated to the prophylaxis, as anti-CMV prophylaxis was not given in both periods. Importantly, there were no differences in the significantly independent adverse factors (that is, invasive aspergillosis, venoocclusive disease and BSI).
Discussion
The results of the current study showed that BSI negatively impacted the post-HSCT 6-month survival and LOH stay. Moreover, compared with the old prophylactic protocol, the addition of levofloxacin in the new antibiotic prophylaxis did not affect the time to BSI development, 6-month mortality, and the distribution of Gram-positive or Gramnegative pathogens (Table 4) . However, this levofloxacinbased prophylactic regimen may be associated with an increase in resistant GNB to other antibiotics, including the third-generation cephalosporins and carbapenem, and probably is associated with increased MDR and ceftazidime-resistant strains. The finding that BSIs are associated with increased mortality in adult allogeneic HSCT recipients, to no surprise, is consistent with the bulk of literature, [3] [4] [5] 40, 54, 55 in contrast to a minority of reports showing no difference. 56 Theoretically, if given patients with or without BSIs did not differ in baseline characteristics, those with BSIs would have increased mortality attributable to offending pathogens. Indeed, in our study, multivariate analysis demonstrated that BSIs were independently associated with poorer post-HSCT 6-month survival. Similarly, by calculating the attributable mortality of BSI, in addition to the Kaplan-Meier estimation, Poutsiaka et al. 2 showed that BSIs are associated with increased mortality up to 2 years post-HSCT. 2 In agreement with the previous literature, 7 our results showed that BSIs substantially occur in 24.8% of allogeneic HSCT recipients despite antibiotic prophylaxis. Another finding that showed a predominance of Gram-negative BSIs in the current study was consistent with those reported by some institutions in Taiwan, 57,58 but in contrast to numerous studies that have found a predominance of Gram-positive bacteria. [1] [2] [3] [4] [5] 40, 55, 59 Literature from other countries in general showed a trend shifting from GNB predominance to Gram-positive bacteria predominance. 3, [60] [61] [62] [63] Changing trends of nosocomial BSIs pathogens over time, variations among institutional or geographic epidemiology of nosocomial BSIs, and variations of prophylactic antibiotics applied may account for this discrepancy.
In the current study, the different antibiotics in the old and new protocols were oral vancomycin vs oral metronidazole, oral nystatin vs oral fluconazole, and no quinolone vs levofloxacin. The purpose of our old prophylactic protocol is to decrease the risk of infection and acute GVHD through the so-called gut decontamination, and the new protocol is aimed to provide more effective systemic anti-fungal and anti-bacterial protection in addition to gut decontamination. Indeed, past studies have shown that selective gut decontamination may reduce severe infections, incidence of multiple-organ dysfunction syndrome, and may lower the risk of acute GVHD. [64] [65] [66] [67] [68] [69] [70] Interestingly, both of our two prophylactic protocols seemed to be equally effective in terms of reducing BSIs. However, an incidental, but possibly important finding was the increase in resistant GNB to potent antibiotics that are commonly used in the treatment of febrile neutropenia. This is particularly worrisome because this type of antibiotic resistance may hamper the management of GNB BSIs after HSCT. The exact mechanism underlying our finding, though remains to be elucidated, may represent an example of the so-called 'collateral damage,' a term referring to the ecological adverse effects of antibiotic therapy, 71 which is believed to be driven largely by antibiotic selection pressure, and promoted by the spreading of plasmid-mediated antimicrobial-resistant genes within the progeny strains or unrelated resistant strains. 72, 73 As mentioned earlier, fluoroquinolone is one of the most common agents linked to this collateral damage, that is, the emergence of various kinds of pathogens. [21] [22] [23] [24] [25] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] 71 However, the patterns of emergence vary among studies; no single study has demonstrated the impact of fluoroquinolone use on all of the specific antibiotic-resistant patterns. Differences in the hospital environments, hospital infection control policies, local microbial epidemiology, patient population and treatments, technology, or even study designs may influence the conclusion. Nevertheless, the emergence of crossresistant strains to other antibiotics should be considered when weighing the benefit against the risk of antibiotic prophylaxis protocols. The increased difficulty in eradicating MDR bacteria may worsen the prognosis in patients with breakthrough infections.
A limitation of the current study is its retrospective design, which is subject to patient selection bias. Moreover, change of prophylaxis was not limited to the use of a quinolone-based regimen; the new regimen included metronidazole, which may have contributed to the suppression of the 'protective effect' of normal anaerobic gut flora. The finding of an increased incidence of third-generation cephalosporins and carbapenem resistance may also reflect influences on the microbial flora unrelated to the regimen chosen for antimicrobial prophylaxis, that is, trends of antimicrobial use in the hospital and geographic region, which could not be demonstrated from the current study. Moreover, resistance to ceftazidime is rising worldwide because of increased use and exposure of bacteria to the drug over time. 74 For that reason, many have switched to cefepime or other newly developed antibiotics, thereby limiting the application of our finding.
In summary, our study confirmed that BSIs are still significantly associated with increased mortality and prolonged LOH stays after allogeneic HSCT, even in recipients taking antibiotic prophylaxis. Levofloxacinbased antibiotic prophylaxis may be associated with collateral damage despite providing similar protection compared with a non-levofloxacin-based regimen. The emergence of cross-resistant strains should be considered when weighing the benefit against the risk of antibiotic prophylaxis protocols for allogeneic HSCT.
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